Altamira Therapeutics Ltd. (CYTOF)

OTCMKTS · Delayed Price · Currency is USD

0.0900

+0.010012 (12.52%)

At close: Oct 15, 2026

Altamira Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Income	-5.56	-6.85	-6.58	-5.94	-5.86	-5.97
Net Income	-5.65	-8.46	-4.31	-27.78	-18.71	-9.27
Earnings Per Share	-1.31	-2.99	-8.77	-610.03	-565.06	-616.45
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Investments	0	1	0.73	0.02	1.08	12.73
Total Debt	0.79	0.36	0.12	6.84	0.63	0.59
Net Cash (Debt)	-0.79	0.64	0.62	-6.83	0.45	12.13
Net Cash Growth	-	3.62%	-	-	-96.31%	748.62%
Net Cash Per Share	-0.18	0.23	1.25	-149.93	13.53	807.00

Cash Flow & CapEx

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Cash Flow	-4.29	-6.11	-12.81	-9.09	-15	-5.47
Capital Expenditures	-0.1	-0.1	-	-	-	-
Free Cash Flow	-4.4	-6.22	-12.81	-9.09	-15	-5.47
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.